Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

被引：0
|
作者：
Monica Tang
Andrea L. Schaffer
Belinda E. Kiely
Benjamin Daniels
Chee K. Lee
Robert J. Simes
Sallie-Anne Pearson
机构：
[1] University of New South Wales,Centre for Big Data Research in Health
[2] University of Sydney,NHMRC Clinical Trials Centre
来源：
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词：
Breast neoplasms; Human epidermal growth factor 2; Trastuzumab; Heart function tests; Observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：893 / 902
页数：9
相关论文
共 50 条
  • [41] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [42] Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer
    Alfred I. Neugut
    Grace Clarke Hillyer
    Lawrence H. Kushi
    Lois Lamerato
    Nicole Leoce
    Christine B. Ambrosone
    Dana H. Bovbjerg
    Jeanne S. Mandelblatt
    Dawn L. Hershman
    Breast Cancer, 2014, 21 : 780 - 785
  • [43] Should trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer?
    Montemurro, Filippo
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 541 - 546
  • [44] A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
    De Cock, Erwin
    Pivot, Xavier
    Hauser, Nik
    Verma, Sunil
    Kritikou, Persefoni
    Millar, Douglas
    Knoop, Ann
    CANCER MEDICINE, 2016, 5 (03): : 389 - 397
  • [45] Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
    Kanomata, Naoki
    Kurebayashi, Junichi
    Moriya, Takuya
    MEDICAL MOLECULAR MORPHOLOGY, 2019, 52 (02) : 106 - 113
  • [46] Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab
    Naoki Kanomata
    Junichi Kurebayashi
    Takuya Moriya
    Medical Molecular Morphology, 2019, 52 : 106 - 113
  • [47] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [48] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Volkmar Müller
    Michael Clemens
    Jacek Jassem
    Nedal Al-Sakaff
    Petra Auclair
    Eveline Nüesch
    Debbie Holloway
    Mona Shing
    Yung-Jue Bang
    BMC Cancer, 18
  • [49] Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer
    Konishi, Takaaki
    Fujiogi, Michimasa
    Michihata, Nobuaki
    Ohbe, Hiroyuki
    Matsui, Hiroki
    Fushimi, Kiyohide
    Tanabe, Masahiko
    Seto, Yasuyuki
    Yasunaga, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (10) : 1115 - 1123
  • [50] Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers
    Sibert, Nora Tabea
    Wesselmann, Simone
    Breidenbach, Clara
    Blohmer, Jens
    Brueckner, Barbara
    Gebauer, Gerhard
    Guilherme, Marina dos Santos
    Hartkopf, Andreas
    Lindner, Christoph
    Peschel, Susanne
    Rieger, Lorenz
    Schad, Friedemann
    Strecker, Paul
    Ferencz, Julia
    Dieng, Sebastian
    Inwald, Elisabeth C.
    Kowalski, Christoph
    Ortmann, Olaf
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (03) : 719 - 726
12345